Here are the 10-Q quarterly reports from Agentix Corp (AGTX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AGTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AGTX filings page.
Agentix Corp. reported a six-month net loss of $208,699 for the period ended September 30, 2026, compared with $329,931 a year earlier, and no revenue in either six-month period. Net cash used in operating activities was $29,894, compared with $115,367; financing provided $33,250 from note borrowings.
At September 30, 2026, cash was $1,312, negative working capital was $3,807,025 and current liabilities were $3,808,337. Management said cash was insufficient to support daily operations and that funding was needed to complete the company’s plan and cover operating expenses for the next 12 months. It said the business would likely fail without financing.
Agentix reported an accumulated deficit of $7,215,863 and concluded that disclosure controls and procedures were not effective as of September 30, 2026. Related-party note principal outstanding was $386,700, with accrued interest of $187,567 as of that date.
Agentix Corp, a clinical-stage biotechnology company focused on metabolic diseases, reported another loss for the quarter ended June 30, 2026 with no revenue. Operating expenses fell to $95,504 from $200,342 a year earlier, mainly due to reduced research and development spending, leading to a narrower net loss of $117,674 versus $185,824.
The balance sheet is highly stressed, with cash of $38, total assets of $38, current liabilities of $3,713,831, and a stockholders’ deficit of $(3,713,793). Related-party payables totaled over $2.45 million, and a related-party mezzanine note of $379,700 is secured by substantially all company assets and accrues interest at 2% per month after an initial period.
Management states there is substantial doubt about the company’s ability to continue as a going concern and indicates a need for additional equity or debt financing, which could dilute existing shareholders or carry unfavorable terms. Management also concluded that disclosure controls and procedures were not effective as of June 30, 2026.
Agentix Corp. reported another loss in its quarter ended December 31, 2025, with net loss of $78,595 for the quarter and $408,526 for the nine months, on no revenue. Cash was only $6,396 against current liabilities of $3,504,396, and accumulated deficit reached $6,930,054, leading management to state there is substantial doubt about the company’s ability to continue as a going concern. Operations are being funded largely through related-party payables and a secured note from Gray’s Peak, and disclosure controls and procedures were deemed not effective as of December 31, 2025.
Agentix Corp. (AGTX), a clinical-stage biotech focused on metabolic diseases, reported no revenue for the three and six months ended September 30, 2025 and remains pre-commercial. The company posted a net loss of $144,107 for the quarter and $329,931 for the six-month period, compared with losses of $90,669 and $241,386 a year earlier, as higher professional and research and development costs and rising interest expense outweighed tight general and administrative spending.
Agentix ended the period with just $5,601 in cash and total current liabilities of $3,423,639, including significant related-party payables and a related-party note payable of $343,350. The accumulated deficit reached $6,851,459, and management concludes these conditions raise substantial doubt about the company’s ability to continue as a going concern without new financing. Common shares outstanding were 40,066,951 as of September 30, 2025.